HSD11B2: Potential Drug Targets for Neurodegenerative Diseases

Target Name: HSD11B2

NCBI ID: G3291

HSD11B2

HSD11B2: Potential Drug Targets for Neurodegenerative Diseases

HSD11B2 (HSD2) is a non-coding RNA molecule that has been identified as a potential drug target in the field of neurodegenerative diseases. HSD11B2 is a key regulator of the heat shock protein (HSP) gene family, which are involved in the stress response of cells. The HSP protein plays a crucial role in maintaining cellular homeostasis and has been implicated in a wide range of cellular processes, including stress response, protein folding, and cellular signaling.

HSD11B2 has been shown to be abnormally expressed in the brains of individuals with Alzheimer's disease, a leading cause of dementia. Furthermore, studies have suggested that HSD11B2 may be involved in the regulation of neurotransmitter release and synaptic plasticity, which are important for the function of the brain.

Drug Target Potential

The potential drug targets for HSD11B2 are vast and varied. One of the most promising targets is the neurotransmitter serotonin, which is involved in mood regulation and other physiological processes.

Serotonin is known to interact with the HSP70 protein, which is a known drug target for Alzheimer's disease. HSP70 has been shown to play a role in the clearance of damaged or misfolded proteins, including the neurotransmitter serotonin. Therefore, drugs that can inhibit HSP70 function may be effective in reducing the production of misfolded proteins and improving the stability of functional HSP70.

Another potential drug target for HSD11B2 is the protein heat shock protein (HSP100), which is involved in the regulation of protein folding and stability. HSP100 is known to interact with HSD11B2, which may influence the regulation of HSP100 function. Therefore, drugs that can modify HSP100 function, such as by increasing its stability or by inhibiting its activity, may be effective in reducing the production of misfolded proteins.

Another potential drug target for HSD11B2 is the protein heat shock protein (HSP90), which is involved in the regulation of protein-protein interactions and cell signaling. HSP90 has been shown to interact with HSD11B2, which may influence the regulation of HSP90 function. Therefore, drugs that can modify HSP90 function, such as by increasing its stability or by inhibiting its activity, may be effective in reducing the production of misfolded proteins.

Methods

To determine the drug targets for HSD11B2, researchers have used a variety of techniques, including RNA sequencing, mass spectrometry, and biochemical assays. RNA sequencing has been used to identify potential RNA binding partners of HSD11B2 and to determine the expression levels of HSD11B2 in different tissues and organisms. Mass spectrometry has been used to identify potential protein binding partners of HSD11B2 and to determine the structure-activity interactions between HSD11B2 and its protein binding partners. Biochemical assays, such as protein-protein interactions and cell signaling assays, have been used to further validate the potential drug targets for HSD11B2.

Conclusion

HSD11B2 is a non-coding RNA molecule that has been identified as a potential drug target in the field of neurodegenerative diseases. The HSP protein plays a crucial role in maintaining cellular homeostasis and has been implicated in a wide range of cellular processes. The potential drug targets for HSD11B2 are vast and varied, including the neurotransmitter serotonin, the protein heat shock protein (HSP100), and the protein heat shock protein (HSP90). Further research is needed to determine the full extent of the

Protein Name: Hydroxysteroid 11-beta Dehydrogenase 2

Functions: Catalyzes the conversion of biologically active 11beta-hydroxyglucocorticoids (11beta-hydroxysteroid) such as cortisol, to inactive 11-ketoglucocorticoids (11-oxosteroid) such as cortisone, in the presence of NAD(+) (PubMed:7859916, PubMed:8538347, PubMed:10497248, PubMed:22796344, PubMed:27927697, PubMed:30902677, PubMed:33387577, PubMed:12788846, PubMed:17314322). Functions as a dehydrogenase (oxidase), thereby decreasing the concentration of active glucocorticoids, thus protecting the nonselective mineralocorticoid receptor from occupation by glucocorticoids (PubMed:7859916, PubMed:10497248, PubMed:33387577, PubMed:12788846, PubMed:17314322). Plays an important role in maintaining glucocorticoids balance during preimplantation and protects the fetus from excessive maternal corticosterone exposure (By similarity). Catalyzes the oxidation of 11beta-hydroxytestosterone (11beta,17beta-dihydroxyandrost-4-ene-3-one) to 11-ketotestosterone (17beta-hydroxyandrost-4-ene-3,11-dione), a major bioactive androgen (PubMed:22796344, PubMed:27927697). Catalyzes the conversion of 11beta-hydroxyandrostenedione (11beta-hydroxyandrost-4-ene-3,17-dione) to 11-ketoandrostenedione (androst-4-ene-3,11,17-trione), which can be further metabolized to 11-ketotestosterone (PubMed:27927697). Converts 7-beta-25-dihydroxycholesterol to 7-oxo-25-hydroxycholesterol in vitro (PubMed:30902677). 7-beta-25-dihydroxycholesterol (not 7-oxo-25-hydroxycholesterol) acts as ligand for the G-protein-coupled receptor (GPCR) Epstein-Barr virus-induced gene 2 (EBI2) and may thereby regulate immune cell migration (PubMed:30902677). May protect ovulating oocytes and fertilizing spermatozoa from the adverse effects of cortisol (By similarity)

The "HSD11B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD11B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets